US 12,116,408 B2
Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
Anette Henriksen, Alleroed (DK); Kristian Kjaergaard, Ballerup (DK); Vibeke Westphal Stennicke, Kokkedal (DK); and Charlotte Wiberg, Bjärred (SE)
Assigned to NOVO NORDISK A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Jul. 20, 2021, as Appl. No. 17/380,404.
Application 16/203,327 is a division of application No. 15/325,865, granted, now 10,179,814, issued on Jan. 15, 2019, previously published as PCT/EP2015/066501, filed on Jul. 17, 2015.
Application 17/380,404 is a continuation of application No. 16/203,327, filed on Nov. 28, 2018, granted, now 11,072,654.
Claims priority of application No. 14177547 (EP), filed on Jul. 17, 2014; and application No. 14194893 (EP), filed on Nov. 26, 2014.
Prior Publication US 2022/0010012 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 2299/00 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 11 Claims
 
1. An antibody or fragment thereof that is capable of binding to and blocking TREM-1, wherein:
the antibody or fragment thereof has a viscosity of less than 5 cP at a concentration of 80 mg/mL; and
the antibody or fragment thereof comprises a variant of SEQ ID NO: 3 wherein at least one or both of E27 and E97 of the CDR1 and CDR3 regions of SEQ ID NO: 3 is substituted with an amino acid residue selected from the group consisting of glycine, alanine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.